Level 5 Insights is Your Strategic Rare Disease Insights Partner

Built on community trust, behavioral truth, and operational rigor — driving clarity and confidence for high-stakes rare disease launches.

We Understand the Challenges You Face

  • Rare disease launches are complex, high-risk, and resource-constrained

  • Conventional research vendors lack rare disease focus and patient access

  • Launch decisions require precision, speed, and strategic insight

  • Every misstep cost time, money, and competitive advantage

Level 5 is not just another vendor. We are a strategic partner for pharma navigating first launches and growth in competitive markets.

Over 30% of our studies focused on rare disease, with expertise in ultra-rare populations.

Our Solution

  • Senior-led, rare disease expertise

  • Deep patient and caregiver community trust

  • Strategic researchers who engage rare communities with genuine empathy

  • Rigorous qualitative and quantitative research capabilities

  • Insights driving launch decisions and securing market growth

Our Unique Strengths

  • Built for small-mid size teams managing 1–3 rare assets

  • Unparalleled access via advocacy and community partnerships

  • Rigorous qualitative and quantitative research capabilities

  • Industry-leading empathetic moderation driving authentic insights

How We Deliver Value

  • Custom research packages aligned with launch milestones

  • Actionable insights tailored for go/no-go, positioning, access, messaging, and label expansion decisions

  • HIPAA compliant AI-environments that accelerate analysis and recommendations

  • Clear, concise deliverables that drive confident, timely decision-making

  • Repeatable frameworks that accelerate launch readiness

Being able to deliver really insightful research. And really being kind of that strategic partner, not just ‘we’re the market research company that you hired to do this study for you.’ It’s more of a partnership, and more consultative.
— Market Research Manager, Fortune 50 Pharmaceutical Company